Montréal- and Berlin-based Reliant AI came out of stealth yesterday with US$11.3 million in funding, co-led by Tola Capital and Inovia Capital, to build a generative AI that can help biopharma clients navigate the complex web of information in research papers. It’s aiming for Tabular, its first product, to provide the accuracy that research-based fields need — and that AI has typically struggled with.